作者
George Lau,Ghassan K. Abou‐Alfa,Ann‐Lii Cheng,Wattana Sukeepaisarnjaroen,Tu Van Dao,Yoon‐Koo Kang,CT Satheesh,Masatoshi Kudo,Bruno Sangro,Robin Kate Kelley,Junji Furuse,Joong‐Won Park,Patrapim Sunpaweravong,Angelica Fasolo,Thomas Yau,Tomokazu Kawaoka,Sérgio Jobim Azevedo,María Reig,Éric Assenat,Mark Yarchoan,Aiwu Ruth He,Mallory Makowsky,Charu Gupta,Alejandra Negro,Stephen L. Chan
摘要
In the global, phase III HIMALAYA study in unresectable hepatocellular carcinoma (uHCC), STRIDE (Single Tremelimumab Regular Interval Durvalumab) improved overall survival (OS) vs. sorafenib; durvalumab was noninferior to sorafenib. HBV is the predominant HCC aetiology in most of Asia vs. HCV or nonviral aetiologies in Western countries and Japan. This analysis evaluated safety and efficacy outcomes for STRIDE and durvalumab monotherapy vs. sorafenib, in HIMALAYA participants enrolled in Asia, excluding Japan.